Investigational drug · Phase 2
Solrikitug
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Eosinophilic Esophagitis (EoE), COPD.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Solrikitug"
First trial start
2024
Aug 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Solrikitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Eosinophilic Esophagitis (EoE)
- COPD
Approved drugs for the same conditions: COPD · Eosinophilic esophagitis · Respiratory · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Solrikitug" as an intervention, largest first.
- A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic EsophagitisPivotal-lookingActive, not recruiting
Uniquity One (UNI)Industry
NCT06598462 · 184 participants · Start Oct 16, 2024 · Primary completion Apr 30, 2027
Drug: Solrikitug Low Dose; Solrikitug Mid Dose and 1 more · For: Eosinophilic Esophagitis (EoE)
Sites: Dothan, Alabama; Glendale, Arizona; Peoria, Arizona · 73 sites in all
- A Study to Evaluate Solrikitug in Participants With COPD (ZION)Pivotal-lookingActive, not recruiting
Uniquity One (UNI)Industry
NCT06496620 · 182 participants · Start Aug 14, 2024 · Primary completion Sep 23, 2026
Drug: Biological: Solrikitug low dose; Biological: Solrikitug high dose · For: COPD
Sites: Birmingham, Alabama; Sheffield, Alabama; Peoria, Arizona · 110 sites in all
- A Study to Evaluate Solriktug in Adult Participants With AsthmaPivotal-lookingCompleted
Uniquity One (UNI)Industry
NCT06496607 · 145 participants · Start Jul 26, 2024 · Primary completion Jul 6, 2026
Drug: NSI-8226; NSI-8226 and 2 more · For: Asthma
Sites: Mobile, Alabama; Peoria, Arizona; Encinitas, California · 69 sites in all
Uniquity One (UNI)Industry
NCT06868082 · 32 participants · Start Jun 20, 2025 · Primary completion Feb 2, 2026
Drug: Solrikitug; Solrikitug · For: Healthy
Sites: Brisbane, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition.
Corren J, Borish L, Brightling C, et al. · J Allergy Clin Immunol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.